百奧賽圖－Ｂ：2022年度報告.pdf

1、Stock code 股份代號：2315百奧賽圖北京醫藥科技股份有限公司Biocytogen Pharmaceuticals(Beijing)Co.,Ltd.(A joint stock company incorporated in the Peoples Republic of China with limited liability)（於中華人民共和國註冊成立的股份有限公司）Annual Report年 度 報 告 20221 1百奧賽圖(北京)醫藥科技股份有限公司 二零二二年年報目錄 Contents主席報告2Chairmans Statement管理層討論與分析6Management

2、 Discussion and Analysis董事、監事及高級管理層46Directors,Supervisors and Senior Management企業管治報告62Corporate Governance Report董事會報告87Directors Report環境、社會及管治報告 132 Environmental,Social and Governance Report附錄一：環境關鍵績效指標摘要171 Appendix I:Environmental Key Performance Indicators Summary Table附錄二：聯交所 環境、社會及管治報告指引 索

3、引173 Appendix II:Index of HKEXs Environmental,Social and Governance Reporting Guide獨立核數師報告 179 Independent Auditors Report綜合損益及其他全面收入表186 Consolidated Statements of Profit or Loss and Other Comprehensive Income綜合財務狀況表 187 Consolidated Statements of Financial Position綜合權益變動表 189 Consolidated Statemen

4、ts of Changes in Equity綜合現金流量表 190 Consolidated Cash Flow Statements綜合財務報表附註 193 Notes to the Consolidated Financial Statements財務概要 311 Financial Summary釋義 312 Definition公司資料 325 Corporate Information2Biocytogen Pharmaceuticals(Beijing)Co.,Ltd.Annual Report 2022主席報告 Chairmans StatementDear distingui

5、shed shareholders,First of all,I would like to express my heartfelt gratitude to all of you for trusting and supporting Biocytogen.I am delighted to announce on behalf of the Board the Companys first annual report for the year ended December 31,2022.In 2022,Biocytogen reaped inspiring results buckin

6、g multiple challenges in the external environment.We saw a hike in operating revenue,a continuous stream of technological innovations and accelerating global cooperation,and secured listing on the Main Board of the Hong Kong Stock Exchange in September.In the annual report,we are very pleased to sha